• Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=8782485; PubMed=15287027; PubMed=33802339).
  

PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x
Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O., Rytomaa T.
p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines.
Cell Prolif. 29:219-230(1996)

PubMed=15287027; DOI=10.1002/gcc.20066
Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y., Grenman R., Fisher S.G., Carey T.E.
Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer.
Genes Chromosomes Cancer 41:145-154(2004)

PubMed=16715129; DOI=10.1038/sj.onc.1209690
Jarvinen A.-K., Autio R., Haapa-Paananen S., Wolf M., Saarela M., Grenman R., Leivo I., Kallioniemi O.-P., Makitie A.A., Monni O.
Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses.
Oncogene 25:6997-7008(2006)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=26694163; DOI=10.1371/journal.pone.0144924; PMCID=PMC4692263
Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.
Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.
PLoS ONE 10:E0144924-E0144924(2015)

PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733
Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A., Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M., Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.
Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.
Mol. Cancer Ther. 17:2060-2071(2018)

PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)

PubMed=33802339; DOI=10.3390/cancers13051069; PMCID=PMC7959143
Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.
Genotyping and characterization of HPV status, hypoxia, and radiosensitivity in 22 head and neck cancer cell lines.
Cancers (Basel) 13:1069.1-1069.12(2021)